Key Developments: Sun Pharmaceutical Industries Ltd (SUN.BO)

SUN.BO on Bombay Stock Exchange

741.45INR
11 Jul 2014
Price Change (% chg)

Rs16.50 (+2.28%)
Prev Close
Rs724.95
Open
Rs725.00
Day's High
Rs751.20
Day's Low
Rs719.75
Volume
139,109
Avg. Vol
189,418
52-wk High
Rs751.20
52-wk Low
Rs475.60

Search Stocks

Latest Key Developments (Source: Significant Developments)

Sun Pharmaceutical Industries Ltd Says Issues With USFDA At Caraco Facility Addressed - Business Standard
Monday, 28 Oct 2013 06:00am EDT 

Business Standard reported that Sun Pharmaceutical Industries Ltd has addressed the US health regulator's concerns about manufacturing lapses at its US based Caraco Pharmaceutical Laboratories. United States Food and Drug Administration had conducted inspections in January and May this year and had noticed the lapses. When asked about the nature of lapses and the corrective measures the Company has taken, a Sun Pharmaceutical spokesperson said they were minor observations. The Company has responded to these a long time back, the spokesperson said without elaborating. Earlier in the August 2012, Sun Pharmaceutical Industries had said American health regulator had approved resumption of manufacturing operations at Caraco for two drugs after inspections of facilities. Subsequent to inspections and corrective action, the USFDA had determined Caraco to be in compliance with relevant paragraphs of the consent decree, Sun Pharma had said. Therefore, US Food and Drug Administration (USFDA) had notified that Caraco may resume operations at its manufacturing facility and packaging sites in Detroit and Wixom, Michigan, it added.  Full Article

Sun Pharmaceutical Industries Ltd's Subsidiary And Intrexon Form Joint Venture To Develop New Class Of Therapeutics For Ocular Diseases
Tuesday, 1 Oct 2013 07:21am EDT 

Sun Pharmaceutical Industries Ltd, through its subsidiary and Intrexon Corp announced the formation of joint venture to develop controllable gene-based therapics for the treatment of ocular diseases that cause partial or total blindness in millions of people worldwide. The joint venture will leverage Sun Pharma's global capabilities and experience in developing and manufacturing complex dosage forms and specialty pharmaceuticals for niche therapy areas. Intrexon and Sun Pharma will share in both the financing of, and the revenues from, the joint venture. Through an exclusive channel collaboration (ECC), the joint venture will have access to Intrexon's full suite of synthetic biology technologies, including the RheoSwitch Therapeutic System (RTS) platform.  Full Article

Sun Pharmaceutical Industries Ltd's Subsidiary Announces US FDA Approval For Generic Version Of Prevacid
Sunday, 15 Sep 2013 10:33pm EDT 

Sun Pharmaceutical Industries Ltd announced that the US FDA has granted its subsidiary final approval for its Abbreviated New Drug Applications (ANDA) for generic version of Prevacid, Lansoprazole Delayed-Release Capsules USP, 15 mg and 30 mg.  Full Article

Sun Pharmaceutical Industries Ltd's Subsidiary Secures USFDA Approval For Generic Prandin
Thursday, 11 Jul 2013 10:47pm EDT 

Sun Pharmaceutical Industries Ltd announced that the US FDA has granted subsidiary final approval for Abbreviated New Drug Applications (ANDA) for generic version of Prandin , Repaglinide tablets. Repaglinide tablets, 1 mg and 2 mg are therapeutic equivalents of Novo Nordisk‚Äôs Prandin tablets. These tablets have annual sales of approximately USD 200 million in the US. Repaglinide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type-2 diabetes mellitus.  Full Article

USFDA Gives Nod For Riluzole Tablets To Sun Pharmaceutical Industries Ltd, Glenmark Pharmaceuticals Ltd's Glenmark Generics-Business Line
Thursday, 20 Jun 2013 08:00pm EDT 

Business Line reported that Sun Pharmaceutical Industries Ltd and Glenmark Generics have got approval from US health regulator to sell generic versions of nervous system disorder treatment drug Riluzole. As per the United States Food and Drug Administration (USFDA) web site, the approvals were given for generic Riluzole oral tablets in the strength of 50 mg. Riluzole is indicated for treatment of amyotrophic lateral sclerosis.  Full Article

Teva Pharmaceutical Industries Ltd and Sun Pharmaceutical Industries Ltd To Pay $2.15 Billion To Settle Pfizer Inc's and Partner Takeda Pharmaceutical Co Ltd's Patent Suit-Reuters
Wednesday, 12 Jun 2013 09:20am EDT 

Reuters reported that Pfizer Inc said Teva Pharmaceuticals Industries Ltd and Sun Pharmaceutical Industries Ltd would pay $2.15 billion to settle a patent infringement lawsuit related to its acid-reflux drug Protonix. Takeda Pharmaceutical Co Ltd, Pfizer's partner on the drug, will receive 36% or about $774 million from the settlement.  Full Article

Sun Pharmaceutical Industries Ltd Sues Novartis In US Court-Business Standard
Tuesday, 11 Jun 2013 03:15pm EDT 

Business Standard reported that Sun Pharmaceutical Industries Ltd has sued Novartis Pharmaceuticals Corp in the District Court of New Jersey, demanding rights to launch a generic version of the cancer drug before the Novartis patent expires. According to an industry source, the law suit filed by Sun Pharma Global FZE - Sun Pharma's US subsidiary -seeks a declaratory judgement against Novartis, allowing the Mumbai-based drug maker to sell generic imatinib mesylate in the US before one of the patents of the drug expires in the market. Imatinib mesylate is an active ingredient of Gleevec.  Full Article

Sun Pharmaceutical Industries Ltd Announces USFDA Approval For Generic Depo-Testosterone Injection
Tuesday, 4 Jun 2013 06:30am EDT 

Sun Pharmaceutical Industries Ltd announced that it has received final approval from the USFDA for its Abbreviated New Drug Application (ANDA) for generic version of Depo-Testosterone Injection, Testosterone Cypionate Injection USP, 100 mg/ml and 200mg/ml. This generic Testosterone Cypionate Injection USP, 100 mg/mL and 200mg/mL is therapeutically equivalent to Depo-Testosterone Injection of Pfizer Inc and is indicated for replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone. As per April-2013, IMS MAT, the product had annual revenues of approximately USD130 million in the US.  Full Article

Sun Pharmaceutical Industries Ltd In Talks To Buy Sweden's Meda AB For $5-$6 Billion-Business Standard
Thursday, 30 May 2013 03:16pm EDT 

Business Standard reported that Sun Pharmaceutical Industries Ltd is in talks to buy Sweden's Meda AB for between $5 billion and $6 billion to boost its generics business in developed markets, two sources with direct knowledge of the process said. Meda makes speciality products, over-the-counter drugs and branded generics the same areas of focus as Sun.  Full Article

Sun Pharmaceutical Industries Ltd Issues FY 2014 Revenue Guidance Above Analysts' Estimates-Conference Call
Tuesday, 28 May 2013 08:30am EDT 

Sun Pharmaceutical Industries Ltd announced that it expect fiscal 2014 consolidated topline to grow by 18% to 20% over fiscal 2013 at constant currency. The Company reported revenue of INR112.389 billion for fiscal 2013. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenue of INR130.842 billion for fiscal 2014.  Full Article

Indian shares edge higher; defensives surge

* BSE index gains 0.15 pct; NSE ends 0.21 pct higher * Century Textile rallies after investor Damani buys stake * Aban likely to launch up to $150 mln share sale on Friday - sources * Ranbaxy gets FDA approval for Novartis's Diovan generic By Abhishek Vishnoi MUMBAI, June 27 - Indian shares rose on Friday as defensive stocks such as Sun Pharmaceutical Industries and Ranbaxy Laboratories jumped on the U.S. regulator's approval for a key drug while IT stocks gained

Search Stocks